The LOTUS-7 trial (loncastuximab + glofitimab) illustrates a key principle for using bispecific antibodies safely: combining them with another active, tumor-debulking drug mitigates Cytokine Release Syndrome (CRS). The speaker identifies this as a "thematic" finding, where reducing tumor bulk directly lowers the risk of this major toxicity, making potent combinations more tolerable.

Combining polatuzumab vedotin with bispecific antibodies appears particularly effective for patients with double-hit lymphoma. This is significant because these high-risk patients, who have poor prognoses, were notably excluded from pivotal trials like STAR GLOW, suggesting a potential new standard for this specific subgroup.

A novel trial design used mosinutuzumab monotherapy first in frontline follicular lymphoma, adding lenalidomide only for patients without a complete response. This adaptive approach successfully spared about two-thirds of patients from the added toxicities of lenalidomide while still achieving very high overall efficacy.

While the first-line Polarix trial suggested Polatuzumab's benefit was greater in ABC-subtype DLBCL, the Polargo trial in relapsed patients found no such difference. Both ABC and GCB subtypes benefited significantly from Polatuzumab's addition. This suggests that in the higher-risk relapse setting, overall disease risk trumps cell of origin as the key determinant of treatment benefit.

Contrary to fears based on T-cell engagers in hematologic cancers, CRS with the DLL3 bispecific tarlatamab in SCLC is typically mild and easily managed. An expert describes it as "scary until you're treating patients and then you find that it's pretty anticlimactic," reassuring community oncologists about the therapy's safety profile.

An expert treating DLBCL states they no longer use bispecific antibodies as monotherapy. Combining them with partners like chemotherapy (GemOx) or ADCs (Polatuzumab) raises the complete response rate by 15-20%, offering a better chance of benefit for patients.

Early trial data for single-agent bispecific antibodies in elderly or frail patients with large cell lymphoma reveals surprisingly high efficacy. This success is prompting discussions about a chemotherapy-free future for this population, with combinations like glofitumab-polatuzumab potentially replacing traditional regimens.

In relapsed/refractory mantle cell lymphoma, the bispecific antibody glofitimab is achieving complete remission rates above 75%. This is unprecedented and notably better than existing CAR-T therapy data, suggesting an accessible, off-the-shelf immunotherapy can outperform more complex cellular therapies in this setting.

Emerging data reveals significant synergy when combining antibody-drug conjugates (ADCs) like polatuzumab vedotin with bispecific antibodies like glofitumab. These combinations show impressive results in relapsed/refractory non-Hodgkin lymphoma, signaling a major future direction for developing more potent therapies.